Zeuss LLC dba Zeuss
FDA issued a warning letter to Zeuss LLC dba Zeuss on February 20, 2026, regarding its website marketing of compounded tirzepatide products. The agency found the products misbranded under FDCA sections 502(a) and 502(bb) because the website falsely implied Zeuss was the compounder of the drugs, and made claims suggesting the compounded products were FDA-approved or clinically proven when they are not. FDA demanded a written corrective response within 15 working days and warned that failure to comply could result in seizure or injunction.
Flagged claims (3)
Proven Weight Loss
each batch rigorously tested for efficacy and safety
GLP-1 is a class of medication that mimic naturally produced hormone in a body. It is FDA approved and clinically proven to work treatment for weight loss.
Required actions (5)
Within fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)'s Office of Compliance describing the specific steps you have taken to address any violations.
Addressing the basis for other website claims that could be construed as false or misleading or demonstrating that such claims have been modified or removed in light of FDCA §§ 502(a) and 502(bb)) [21 U.S.C. §§ 352(a) and (bb)].
Identifying the entities that produce the compounded products offered on your website;
Providing a representative sample of labeling for such products;
Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.
Does your site contain similar claims?
The free site audit scans your site against every entry in this Atlas. Most glp-1 / weight loss sites match 3-6 patterns.
Run my free site audit